Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies

Ferreira, Daniel ; Przybelski, Scott A. ; Lesnick, Timothy G. ; Lemstra, Afina W. ; Londos, Elisabet LU ; Blanc, Frederic ; Nedelska, Zuzana ; Schwarz, Christopher G. ; Graff-Radford, Jonathan and Senjem, Matthew L. , et al. (2020) In Neurology 95(24). p.3257-3268
Abstract

OBJECTIVE: In a multicenter cohort of probable dementia with Lewy bodies (DLB), we tested the hypothesis that β-amyloid and tau biomarker positivity increases with age, which is modified by APOE genotype and sex, and that there are isolated and synergistic associations with the clinical phenotype. METHODS: We included 417 patients with DLB (age 45-93 years, 31% women). Positivity on β-amyloid (A+) and tau (T+) biomarkers was determined by CSF β-amyloid1-42 and phosphorylated tau in the European cohort and by Pittsburgh compound B and AV-1451 PET in the Mayo Clinic cohort. Patients were stratified into 4 groups: A-T-, A+T-, A-T+, and A+T+. RESULTS: A-T- was the largest group (39%), followed by A+T- (32%), A+T+ (15%), and A-T+ (13%). The... (More)

OBJECTIVE: In a multicenter cohort of probable dementia with Lewy bodies (DLB), we tested the hypothesis that β-amyloid and tau biomarker positivity increases with age, which is modified by APOE genotype and sex, and that there are isolated and synergistic associations with the clinical phenotype. METHODS: We included 417 patients with DLB (age 45-93 years, 31% women). Positivity on β-amyloid (A+) and tau (T+) biomarkers was determined by CSF β-amyloid1-42 and phosphorylated tau in the European cohort and by Pittsburgh compound B and AV-1451 PET in the Mayo Clinic cohort. Patients were stratified into 4 groups: A-T-, A+T-, A-T+, and A+T+. RESULTS: A-T- was the largest group (39%), followed by A+T- (32%), A+T+ (15%), and A-T+ (13%). The percentage of A-T- decreased with age, and A+ and T+ increased with age in both women and men. A+ increased more in APOE ε4 carriers with age than in noncarriers. A+ was the main predictor of lower cognitive performance when considered together with T+. T+ was associated with a lower frequency of parkinsonism and probable REM sleep behavior disorder. There were no significant interactions between A+ and T+ in relation to the clinical phenotype. CONCLUSIONS: Alzheimer disease pathologic changes are common in DLB and are associated with the clinical phenotype. β-Amyloid is associated with cognitive impairment, and tau pathology is associated with lower frequency of clinical features of DLB. These findings have important implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients with probable DLB, β-amyloid is associated with lower cognitive performance and tau pathology is associated with lower frequency of clinical features of DLB.

(Less)
Please use this url to cite or link to this publication:
@misc{71b0c389-e1dd-4676-bb65-3c5663b86ecd,
  abstract     = {{<p>OBJECTIVE: In a multicenter cohort of probable dementia with Lewy bodies (DLB), we tested the hypothesis that β-amyloid and tau biomarker positivity increases with age, which is modified by APOE genotype and sex, and that there are isolated and synergistic associations with the clinical phenotype. METHODS: We included 417 patients with DLB (age 45-93 years, 31% women). Positivity on β-amyloid (A+) and tau (T+) biomarkers was determined by CSF β-amyloid1-42 and phosphorylated tau in the European cohort and by Pittsburgh compound B and AV-1451 PET in the Mayo Clinic cohort. Patients were stratified into 4 groups: A-T-, A+T-, A-T+, and A+T+. RESULTS: A-T- was the largest group (39%), followed by A+T- (32%), A+T+ (15%), and A-T+ (13%). The percentage of A-T- decreased with age, and A+ and T+ increased with age in both women and men. A+ increased more in APOE ε4 carriers with age than in noncarriers. A+ was the main predictor of lower cognitive performance when considered together with T+. T+ was associated with a lower frequency of parkinsonism and probable REM sleep behavior disorder. There were no significant interactions between A+ and T+ in relation to the clinical phenotype. CONCLUSIONS: Alzheimer disease pathologic changes are common in DLB and are associated with the clinical phenotype. β-Amyloid is associated with cognitive impairment, and tau pathology is associated with lower frequency of clinical features of DLB. These findings have important implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients with probable DLB, β-amyloid is associated with lower cognitive performance and tau pathology is associated with lower frequency of clinical features of DLB.</p>}},
  author       = {{Ferreira, Daniel and Przybelski, Scott A. and Lesnick, Timothy G. and Lemstra, Afina W. and Londos, Elisabet and Blanc, Frederic and Nedelska, Zuzana and Schwarz, Christopher G. and Graff-Radford, Jonathan and Senjem, Matthew L. and Fields, Julie A. and Knopman, David S. and Savica, Rodolfo and Ferman, Tanis J. and Graff-Radford, Neill R. and Lowe, Val J. and Jack, Clifford R. and Petersen, Ronald C. and Mollenhauer, Brit and Garcia-Ptacek, Sara and Abdelnour, Carla and Hort, Jakub and Bonanni, Laura and Oppedal, Ketil and Kramberger, Milica G. and Boeve, Bradley F. and Aarsland, Dag and Westman, Eric and Kantarci, Kejal}},
  issn         = {{1526-632X}},
  language     = {{eng}},
  number       = {{24}},
  pages        = {{3257--3268}},
  publisher    = {{Lippincott Williams & Wilkins}},
  series       = {{Neurology}},
  title        = {{β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies}},
  url          = {{http://dx.doi.org/10.1212/WNL.0000000000010943}},
  doi          = {{10.1212/WNL.0000000000010943}},
  volume       = {{95}},
  year         = {{2020}},
}